2/21/2012 - 12:09 PM EST - Oncolytics Biotech Inc. : announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN® in patients with recurrent or metastatic castration resistant prostate cancer. Oncolytics Biotech Inc.
shares T.ONC are trading up $0.01 at $4.95.
